Role of Raf in vascular protection from distinct apoptotic stimuli

Science

Volumn 301, Issue 5629, 2003, Pages 94-96

  Alavi, Alireza ^a   Hood, John D ^a   Frausto, Ricardo ^a   Stupack, Dwayne G ^a   Cheresh, David A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELLS; CHEMICAL ACTIVATION; NITROGEN;

VASCULAR PROTECTION;

ENZYMES;

BASIC FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN P21; PROTEIN TYROSINE KINASE; RAF PROTEIN; VASCULOTROPIN;

BIOLOGY; PROTEIN;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; CHICK EMBRYO; EMBRYO; ENDOTHELIUM CELL; GENE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROBLAST GROWTH FACTOR 2; FLAVONOIDS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MAP KINASE KINASE 1; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; POINT MUTATION; PROTEIN TRANSPORT; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0038724937     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1082015     Document Type: Article

References (23)

1. B. P. Eliceiri, R. Klemke, S. Stromblad, D. A. Cheresh, J. Cell Biol. 140, 1255 (1998).
2. B. P. Eliceiri et al., Mol. Cell 4, 915 (1999).
3. B. P. Eliceiri et al., J. Cell Biol. 157, 149 (2002).
4. M. Friedlander et al., Science 270, 1500 (1995).
5. J. D. Hood et al., Science 296, 2404 (2002).
6. M. Mikula et al., EMBO J. 20, 1952 (2001).
7. M. Huser et al., EMBO J. 20, 1940 (2001).
8. L. Wojnowski et al., Nature Genet. 16, 293 (1997).
9. R. Marais, Y. Light, H. F. Paterson, C. S. Mason, C. J. Marshall, J. Biol. Chem. 272, 4378 (1997).
10. C. S. Mason et al., EMBO J. 18, 2137 (1999).
11. A. J. King et al., Nature 396, 180 (1998).
12. J. R. Fabian, I. O. Daar, D. K. Morrison, Mol. Cell Biol. 13, 7170 (1993).
13. Z. S. Zhao et al., Mol. Cell Biol. 18, 2153 (1998).
14. K. B. Kaplan et al., EMBO J. 13, 4745 (1994).
15. G. Pearson et al., Endocr. Rev. 22, 153 (2001).
16. R. L. Klemke et al., J. Cell Biol. 137, 481 (1997).
17. A. von Gise et al., Mol. Cell. Biol. 21, 2324 (2001).
18. H. G. Wang, U. R. Rapp, J. C. Reed, Cell 87, 629 (1996).
19. S. M. Frisch, H. Francis, J. Cell Biol. 124, 619 (1994).
20. D. G. Stupack, X. S. Puente, S. Boutsaboualoy, C. M. Storgard, D. A. Cheresh, J. Cell Biol. 155, 459 (2001).
21. G. Klement et al., J. Clin. Invest. 105, R15 (2000).
22. J. Hood, H. J. Granger, J. Biol. Chem. 273, 23504 (1998).
23. We thank M. Marshall for the S9338/339AA and YY340/341FF Raf-1 point mutants, D. Mikolon for assistance with CAM studies, and J.-D. Lee for antibody to ERK5. Supported by NIH grant CA75924 (A.A.) and NIH grants CA50286, CA45726, and P01 CA78045 (D.A.C.). D.A.C. is a shareholder in TargeGen Inc., which is developing inhibitors of Src kinases for treatment of disease.